Generate Biomedicines, Inc. - 10-Q Filing

Generate Biomedicines reports Q3 financial results highlighting ongoing R&D investment and collaboration activity with Amgen, Novartis, and Zealand.

2 articles from 1 source · updated November 12, 2026, 12:16 UTC

Coverage

• Generate Biomedicines, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 12:16 UTC
• Generate Biomedicines, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 12:06 UTC